Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 with Nivolumab +/- Ipilimumab in Solid Tumors
NCT04840589Phase 1Suspended
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZEN3694 in solid tumor and ovarian carcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and tolerability at 6 weeks and Phase 2 recommended dose at 6 weeks. Started Feb 2022; status: suspended.
02
Drugs
ZEN3694
03
Conditions
solid tumorovarian carcinoma
Beyond the preview
Go deeper on NCT04840589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840589.